Herantis Pharma: A Broad-Mechanism Bet in a Thinning Parkinson's Race
With Phase I biomarker data in hand, an EU grant, and a new CMO, Herantis advances HER-096 to Phase II as rivals stumble on narrow targets.
HRTIS.HE · Earnings Call · 2026-08-20
From Phase I Signal to Phase II Ambition
Herantis Pharma’s first-half 2026 report reads less like a routine quarterly update and more like a carefully staged launchpad. The company’s lead asset, HER-096, is moving into a randomized, placebo-controlled Phase II efficacy trial in early-stage Parkinson’s disease. The decision rides on a Phase I dataset that showed not just safety and brain penetration, but what the company interprets as a mechanism of action–consistent biological response. CEO Antti Vuolanto stresses the strength of the evidence: “We have demonstrated favorable safety and tolerability profile. We have demonstrated efficient brain penetration. We also have a strong biomarker data set that suggests a biological response in Parkinson's patients.” — Antti Vuolanto, CEO · 2026-08-20
The trial itself will enroll roughly 100 patients, with a 9-month placebo-controlled phase followed by a 6-month open-label extension. The primary endpoint leans on digital monitoring via a smartphone platform — a choice informed by the failure of Biogen and Denali’s recent programs. As new CMO Juha Savola explains, the goal is to capture subtle changes in motor symptoms that traditional scales miss. “The design has to be creative. The design has to be smart, and smart in a way that we are able, as I said, use every subject in the study to build up understanding if this drug is doing what we are expecting it to do.” — Juha Savola, Chief Medical Officer · 2026-08-20
A Thinning Field for Disease Modification
Herantis is positioning HER-096 as a broad, disease-modifying therapy that targets the core biology of Parkinson’s, rather than a single pathway. This is a deliberate contrast to the immunotherapies, kinase inhibitors, and lysosomal approaches that have dominated the pipeline. The recent discontinuation of Biogen and Denali’s genetic-lysosomal programs in the summer effectively clears the field. Antti notes, “Their approach was targeting a specific kinase target, which is expressed actually in a fraction of patients. But in this trial, they wanted to treat idiopathic, so all comers in a way.” — Antti Vuolanto, CEO · 2026-08-20 That failure does not change Herantis’ plans, but it does quiet the competition. Juha sees it as technical validation: “It is informing us that you can implement a smartphone-based data collection in a quite substantially big phase II study.” — Juha Savola, Chief Medical Officer · 2026-08-20
This is a market with massive clinical need. Parkinson’s affects 10–12 million people today, and the economic burden exceeds $250 billion. There are no approved disease-modifying therapies. The company’s emphasis on neurorestoration — not just slowing progression — sets it apart from cell therapies, which Antti argues are niche and surgically complex. “It can be a limited niche product, but it definitely cannot saturate the market.” — Antti Vuolanto, CEO · 2026-08-20
Financing the Next Step
Execution will require capital. The Phase II trial is expected to cost around €20 million, with total financing needs of €30–35 million. The company secured an €8 million Horizon Europe grant in February, and the EIC Fund remains a potential co-investor under the 2023 term sheet. But cash at end-June stood at just €3.5 million, and equity was negative. CFO Tone Kvåle is blunt: “We need to have more capital to launch the phase II clinical trial, and we are actively exploring different options.” — Tone Kvåle, CFO · 2026-08-20 The company is engaged in partnering discussions, equity financing, and further non-dilutive sources.
Management and Milestones
The appointment of Juha Savola as Chief Medical Officer — a 25-year veteran who previously led gene therapy development at Spark Therapeutics — adds credibility. His rationale for joining is the compelling data: “The evidence Herantis has built around CDNF first and then later on HER-096 is very compelling in the field of any modalities I am aware of or competing products.” — Juha Savola, Chief Medical Officer · 2026-08-20 He also brings a big-pharma perspective on study design and regulatory strategy.
The near-term milestones are clear: submit the clinical trial application by end-2026, first patient dosing in H1 2027, and an interim efficacy readout in early 2029. The FDA has already provided supportive feedback on the Phase II plan, which could streamline a future IND. As Antti puts it, “we are very confident that the timelines that we have communicated, they will hold.” — Antti Vuolanto, CEO · 2026-08-20
For a small-cap biotech, the next 18 months are make-or-break. But with a differentiating mechanistic story, a de-risked Phase I data package, and a narrowing competitive set, Herantis is betting that HER-096 can be the first disease-modifying therapy for Parkinson’s — and that a partner will pay accordingly.